CTOs on the Move

LifeMine Therapeutics

www.lifeminetx.com

 
For thousands of years, people have discovered medicines from fungi by brewery. This approach has led to transformative medicines that saved millions of lives and have altered the course of medical history. Drug discovery by brewery proved to be difficult and time-consuming, leaving the field in search of a disruptive technological solution. Our genomically-enabled drug discovery engine is precisely that solution, dramatically accelerating the search for nature’s breakthrough drugs. At LifeMine, genomicists, bioinformaticians and microbiologists identify new evolutionary solutions for disease intervention; natural products chemists access the natural molecules that inspire our drug discovery efforts; biologist and chemist drug hunters craft these ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.lifeminetx.com
  • 100 Acorn Park Drive 6th Floor
    Cambridge, MA USA 02140
  • Phone: 617.945.9510

Executives

Name Title Contact Details

Funding

LifeMine Therapeutics raised $55M on 09/18/2017
LifeMine Therapeutics raised $50M on 01/07/2021

Similar Companies

Biosplice Therapeutics

Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.

RubrYc Therapeutics

RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.

Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.

Nacalai USA

Nacalai USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alberta Conservation Association

Alberta Conservation Association is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.